Abstracts tagged "psoriasis"

Abstract Number: 2502 • 2019 ACR/ARP Annual Meeting
Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study
Jennifer Belasco¹, Sandra Garcet ¹, Mustimbo roberts ², Judilyn Fuentes-Duculan ¹, Norma Kunjravia ¹, Inna Cueto ¹, Israel Coats ¹, Xuan Li ¹, Philip Mease ³, Alice Gottlieb ⁴, Oliver FitzGerald ⁵ and James Krueger ¹, ¹The Rockefeller University, New York, NY, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ⁵University College Dublin, Dublin, Ireland
Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulation modulator, has been shown to improve disease activity in patients with psoriatic arthritis (PsA), but its effect on…
Abstract Number: 1526 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study
Wendy Cantrell ¹, Patricia Lee ², Emil Tanghetti ³, Alan Mendelsohn⁴, Jeff Parno ⁴, Stephen Rozzo ⁴ and Wilson Liao ⁵, ¹Department of Dermatology, University of Alabama Birmingham, Birmingham, AL, USA; Dermatology at the Whitaker Clinic, Birmingham, AL, USA, Birmingham, AL, ²Center for Clinical Studies, Webster, TX, USA, Webster, TX, ³Center for Dermatology and Laser Surgery, Sacramento, CA, USA, Sacramento, CA, ⁴Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁵Department of Dermatology, University of California San Francisco, San Francisco, CA, USA, San Francisco, CA
Background/Purpose: We assessed residual plaque psoriasis in patients successfully treated with anti–interleukin-23p19 monoclonal antibody tildrakizumab (TIL) who interrupted treatment, relapsed, and were retreated vs continuously…
Abstract Number: 2504 • 2019 ACR/ARP Annual Meeting
Differential Expression of Human Endogenous Retroviruses in Psoriatic Disease
Remy Pollock¹, Rohan Machhar ¹, Laila Zaman ¹, Dafna Gladman ² and Vinod Chandran ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Human endogenous retroviruses (HERV) are the stably inherited remnants of ancient retroviruses that infected the ancestral germline. A growing body of research has associated…
Abstract Number: 1527 • 2019 ACR/ARP Annual Meeting
Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program
Holly Glover ¹, Kristine Kucera ², Alan Mendelsohn³, Jeff Parno ³, Stephen Rozzo ³, Frank Ferritto ⁴ and Renata Block ⁵, ¹Dermatology and Skin Cancer Surgery Center, McKinney, TX, USA, McKinney, TX, ²North Texas Dermatology, Richardson, TX, USA, Richardson, TX, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA, Princeton, NJ, ⁴Polley Dermatology, Wilson, NC, USA, Wilson, NC, ⁵Pinski Dermatology & Cosmetic Surgery, Chicago, IL, USA, Chicago, IL
Background/Purpose: Tildrakizumab (TIL) is a high-affinity, anti–interleukin‐23p19 monoclonal antibody with demonstrated efficacy for the treatment of chronic plaque psoriasis in a phase 2b (P05495 [NCT01225731])…
Abstract Number: 2505 • 2019 ACR/ARP Annual Meeting
Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina
Luciano Fernando Lo Giudice¹, Maria Laura Acosta Felquer ¹, Luis Daniel Mazzuoccolo ², Maria Laura Galimberti ² and Enrique Soriano ³, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: As psoriasis (Pso) commonly precedes psoriatic arthritis (PsA), an important unanswered question is whether treatment of Pso might influence the development of PsA in…
Abstract Number: 1538 • 2019 ACR/ARP Annual Meeting
The Effects of Apremilast Therapy on Deployability in Active Duty U.S. Army Soldiers with Plaque Psoriasis and Psoriatic Arthritis
Andrew Price¹, Vanya Wagler ², Chase Donaldson ¹ and Patrick Mastin ¹, ¹William Beaumont Army Medical Center, El Paso, TX, ²United Regional Physician Group, Wichita Falls, TX
Background/Purpose: Apremilast is a novel oral phosphodiesterase 4 inhibitor that is used for plaque psoriasis (PsO) and psoriatic arthritis (PsA). This medicine is unique in…
Abstract Number: 2743 • 2019 ACR/ARP Annual Meeting
Characterizing the Epigenomic Landscape of Psoriasis Patients Destined to Develop Psoriatic Arthritis
Remy Pollock¹, Rohan Machhar ¹, Vinod Chandran ² and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Approximately 30% of psoriasis patients develop psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, usually after psoriasis onset. A large proportion of individuals with PsA…
Abstract Number: 1556 • 2019 ACR/ARP Annual Meeting
Exposure–Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal Symptoms
Jun Shen¹, Anjaneya Chimalakonda ¹, Miroslawa Nowak ¹, John Throup ¹, Subhashis Banerjee ¹ and Ihab Girgis ¹, ¹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986165 is an oral, selective inhibitor of TYK2, an enzyme that activates signal transducer and activator of transcription (STAT)-dependent cytokine signaling pathways, including the…
Abstract Number: 1912 • 2019 ACR/ARP Annual Meeting
High Dimensional Flowcytometric Profiling Distinguishes Psoriasis and Psoriatic Arthritis
Michelle Mulder¹, Juul van den Reek ², Elke de Jong ², Bram van Cranenbroek ², Ruben Smeets ², Irma Joosten ², Xuehui He ³, Frank van den Hoogen ¹, Hans Koenen ³ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³Radboudumc, Njimegen, Netherlands
Background/Purpose: Psoriasis (Pso) is a common chronic inflammatory skin disease. About 30% of Pso patients develop psoriatic arthritis (PsA), a chronic inflammation of joints and…
Abstract Number: 2092 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-existing Potential Immune Mediated Diseases: A Pooled Post-hoc Analysis on Two Parallel Randomized Trials
Alemnew Dagnew¹, Debora Rausch ², Caroline Hervé ³, Toufik Zahaf ⁴ and Anne Schuind ¹, ¹GSK, Rockville, MD, ²GSK, Philadelphia, PA, ³GSK, Wavre, Belgium, ⁴GSK, Rixensart, Belgium
Background/Purpose: The increased risk of herpes zoster (HZ) in older adults is attributable to age-related decline in immunity. In 2 pivotal studies, ZOE-50 (NCT01165177) and…
Abstract Number: 2904 • 2018 ACR/ARHP Annual Meeting
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients and Healthy Controls
Ralf G. Thiele¹, Yahui Grace Chiu², Nelson Huertas³, Dongge Li⁴, Changyong Feng⁵, Sharon Moorehead⁶, Cristy Bell⁷ and Christopher T. Ritchlin⁸, ¹Division of Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, Division of Allergy, Immunology and Rheumatology, School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ⁵Statistics, University of Rochester, Rochester, NY, ⁶Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, ⁷Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁸Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY
Background/Purpose: The events that underlie the transition from psoriasis (Ps) to psoriatic arthritis (PsA) are not well understood, although up to 30% of Ps patients…
Abstract Number: 640 • 2018 ACR/ARHP Annual Meeting
Increasing Rates of Arthroplasty for Psoriatic Arthritis in the United Kingdom between 1995 and 2010
Ryan Lewinson¹, Isabelle Vallerand², Jeremy LaMothe³, Laurie Parsons¹, Alexandra Frolkis⁴, Mark Lowerison², Scott Patten² and Cheryl Barnabe^2,5, ¹Dermatology, University of Calgary, Calgary, AB, Canada, ²Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Orthopaedic Surgery, University of Calgary, Calgary, AB, Canada, ⁴Internal Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Rheumatology, University of Calgary, Calgary, AB, Canada
Background/Purpose: Arthroplasty requirements among patients with psoriatic arthritis (PsA) are not well known. This information is of importance to clinical and policy stakeholders for health…
Abstract Number: 652 • 2018 ACR/ARHP Annual Meeting
Disease Interception in Psoriasis Patients with Subclinical Joint Inflammation By Interleukin 17 Inhibition with Secukinumab – Data from a Prospective Open Label Study
Eleni Kampylafka¹, Isabelle Oliveira¹, Christina Linz², Veronika Lerchen¹, Matthias Englbrecht¹, David Simon³, Michael Sticherling⁴, Juergen Rech⁵, Arnd Kleyer³, Georg Schett⁶ and Axel J. Hueber³, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, e, Germany, ³Department of Internal Medicine 3—Rheumatology and Immunology, Friedrich-Alexander-University Erlangen–Nürnberg (FAU), Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Department of Dermatology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ⁵Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Musculoskeletal changes precede the onset of psoriatic arthritis (PsA). A subset of psoriasis patients is characterized by arthralgia as well as inflammatory changes in…
Abstract Number: 679 • 2018 ACR/ARHP Annual Meeting
Ultrasonographic Research of the Relationship between Nail Disorders and Peripheral Arthritis or Enthesitis in Patients with Psoriasis and Psoriatic Arthritis
Tadashi Okano¹, Kentaro Inui², Koji Mandai³, Yutaro Yamada⁴, Tatsuya Koike⁵ and Hiroaki Nakamura², ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orthopedic surgery, Yodogawa Christian Hospital, Osaka, Japan, ⁵Center for Senile Degenerative Disorders, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Although skin lesion is the most typical findings in patients with psoriasis (PsO), nail psoriasis is also one of the important clinical manifestation. Moreover,…
Abstract Number: 697 • 2018 ACR/ARHP Annual Meeting
Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit
Clara Pérez-Velásquez¹, Maria Luz Garcia Vivar², Silvia Perez Barrio³, Eva Galindez-Agirregoikoa¹, Esther Ruíz Lucea¹, Ignacio Torre-Salaberri⁴, Olaia Fernández-Berrizbeitia¹, Ana Rosa Inchaurbe Pellejero², Juan Blanco Madrigal¹, Edurne Guerrero Basterretxea², Itziar Calvo Zorrilla², Oihane Ibarguengoitia², David Montero², Natalia Rivera-García¹, Maria Jesus Allande Lopez Linares¹ and Iñigo Gorostiza-Hormaetxe⁵, ¹Rheumatology, University Hospital of Basurto, Bilbao, Spain, ²Rheumatology, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ³Dermatology, University Hospital of Basurto, Bilbao, Spain, ⁴Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ⁵Unit of Research, University Hospital of Basurto, Bilbao, Spain
Background/Purpose: We consider multidisciplinary management necessary, especially in a subgroup of patients with Psoriatic Arthritis (PsA) for complexity, cutaneous and / or joint involvement. Despite…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].